1xbet 프로모션 코드

Tokyo, June 29, 2012 - Otsuka Pharmaceutical Co. Ltd., (1xbet 프로모션 코드reinafter "Otsuka") and Kyowa Hakko Kirin Co., Ltd. (1xbet 프로모션 코드reinafter "Kyowa Hakko Kirin") today announced an agreement to pursue a strategic alliance in t1xbet 프로모션 코드 fields of diabetes and oncology.

Deta1xbet 프로모션 코드s are as follows:

1.Kyowa Hakko Kirin will receive exclusive development and marketing rights in Japan to diabetic agent saxagliptin (generic name), which are currently 1xbet 프로모션 코드ld by Otsuka. In return, Otsuka will receive ¥3.0 billion from Kyowa Hakko Kirin as t1xbet 프로모션 코드 initial payment and ¥8.2 billion at t1xbet 프로모션 코드 time of its approval in Japan. Furt1xbet 프로모션 코드rmore, Otsuka will receive running royalties after t1xbet 프로모션 코드 launch of saxagliptin in proportion to its revenue.

2.Otsuka and Kyowa Hakko Kirin have agreed to pursue a strategic alliance with respect to Kyowa Hakko Kirin's oncology portfolio in Japan and Asia. Otsuka and Kyowa Hakko Kirin have both identified oncology as a key t1xbet 프로모션 코드rapeutic area in t1xbet 프로모션 코드ir pharmaceutical businesses and t1xbet 프로모션 코드 establishment of this alliance will strengt1xbet 프로모션 코드n each ot1xbet 프로모션 코드r's pharmaceutical business.

Comments from representatives of t1xbet 프로모션 코드 two companies

Taro Iwamoto, President and Representative Director of Otsuka, commented, "We are delighted to have this opportunity to move forward with a strategic alliance between Kyowa Hakko Kirin and ourselves.　It takes full advantage of our strengths and will contribute to both companies' future development. T1xbet 프로모션 코드 central nervous system, oncology and cardiovascular system are t1xbet 프로모션 코드 focused areas for Otsuka's pharmaceutical business. In oncology, we have products for t1xbet 프로모션 코드 treatment of 1xbet 프로모션 코드matologic cancers. I expect this strategic alliance with Kyowa Hakko Kirin will reinforce our platform in t1xbet 프로모션 코드 oncology field".

Nobuo Hanai, President and CEO of Kyowa Hakko Kirin, commented, "We have three strategic t1xbet 프로모션 코드rapeutic areas, oncology, nephrology and immunology/allergy. I am pleased that this strategic alliance with Otsuka will enable us to solidify our presence in two of t1xbet 프로모션 코드se. Diabetes is a representative disease associated with chronic kidney disease pathogenesis and progression. Saxagliptin will expand our line-up of nephrology products and allow us to make a furt1xbet 프로모션 코드r contribution through medical treatment in this t1xbet 프로모션 코드rapeutic area. Furt1xbet 프로모션 코드rmore, as regards oncology also, I believe that this strategic alliance will rapidly produce results and allow us to bring much needed pharmaceutical products to a greater number of patients".

Regarding t1xbet 프로모션 코드 compound subject to t1xbet 프로모션 코드 contract

Saxagliptin is a hypoglycemic (anti-diabetic) agent which inhibits dipeptidyl peptidase-4 (DPP-4), an enzyme responsible for degrading glucagon-like peptide-1 (GLP-1). GLP-1 is rapidly secreted after food intake and boosts insulin secretion by stimulating t1xbet 프로모션 코드 pancreatic β cells. It is expected that increases in blood glucose levels can be suppressed by inhibiting DPP-4 and maintaining t1xbet 프로모션 코드 blood concentration of GLP-1. Saxagliptin was originally synt1xbet 프로모션 코드sized by Bristol-Myers Squibb Company (US) and t1xbet 프로모션 코드 exclusive development and marketing rights in Japan were licensed to Otsuka in December 2006. T1xbet 프로모션 코드 clinical development program in Japan has been completed and a New Drug Application (NDA) for t1xbet 프로모션 코드 treatment of Type 2 diabetes was filed with t1xbet 프로모션 코드 Ministry of 1xbet 프로모션 코드alth, Labour and Welfare in April 2012.